Bafilomycin A1: Selective V-ATPase Inhibitor for Lysosomal and pH Regulation Research

Executive Summary: Bafilomycin A1 is a potent, selective, and reversible inhibitor of vacuolar-type H⁺-ATPases (V-ATPases), with IC₅₀ values ranging from 4 to 400 nM depending on organism and assay (APExBIO). At concentrations as low as 10 nM, it completely blocks proton transport in vitro, making it essential for dissecting intracellular pH regulation and lysosomal function (AVL-301). Bafilomycin A1 is widely used to study autophagy, osteoclast-mediated bone resorption, and is foundational for disease modeling in cancer and neurodegeneration (Nature Communications 2024). It demonstrates dose-dependent inhibition of vacuolization in HeLa cells and is highly effective in animal models such as tilapia. Proper handling and storage are critical due to its instability in solution. All claims are supported by peer-reviewed or manufacturer data, ensuring reproducibility and transparency.

Biological Rationale

Bafilomycin A1 is a macrolide antibiotic produced by Streptomyces griseus. It is a highly selective and reversible inhibitor of vacuolar H⁺-ATPases (V-ATPases), enzymes responsible for acidifying intracellular organelles such as lysosomes, endosomes, and the Golgi apparatus (APExBIO). V-ATPases regulate the proton gradient across organellar membranes, which is essential for intracellular pH homeostasis, protein degradation, and autophagic flux. Inhibition of V-ATPases disrupts lysosomal acidification, impairs autophagosome-lysosome fusion, and alters cellular signaling cascades. These processes are central to cancer progression, neurodegeneration, infectious diseases, and bone resorption (Nature Communications 2024).

Mechanism of Action of Bafilomycin A1

Bafilomycin A1 binds specifically to the Vo subunit of V-ATPases, blocking the translocation of protons (H⁺) across organellar membranes. This binding is both selective and reversible, with minimal off-target effects at recommended concentrations (4–400 nM). The compound exhibits high potency, with complete inhibition of proton transport at concentrations as low as 10 nM in vitro. The inhibition process prevents acidification of lysosomes and other acidic vesicles, directly impacting processes such as protein degradation, endocytosis, and autophagic flux (APExBIO; AVL-301).

Bafilomycin A1's mode of action is distinct from other proton pump inhibitors, as it does not affect plasma membrane H⁺-ATPases or mitochondrial F₁F₀-ATPases at standard research concentrations. This specificity underpins its widespread adoption in cell biology and disease modeling workflows (Brefeldin-A.com – This article provides new mechanistic details compared to prior summaries of V-ATPase inhibition).

Evidence & Benchmarks

• Bafilomycin A1 inhibits V-ATPase enzymatic activity with IC₅₀ values of 4–400 nM, depending on the biological source and assay system (APExBIO).
• At 10 nM, Bafilomycin A1 completely blocks V-ATPase-mediated proton transport in vitro (APExBIO).
• In HeLa cells, Bafilomycin A1 dose-dependently inhibits H. pylori-induced vacuolization, with 50% effect at 4 nM and complete inhibition at 12.5 nM, restoring normal morphology (APExBIO).
• In young freshwater tilapias, Bafilomycin A1 inhibits Na⁺ uptake via V-ATPase with a K_i of 1.6 × 10⁻⁷ mol/L, demonstrating efficacy in vivo (APExBIO).
• Bafilomycin A1 is a benchmark tool for perturbing lysosomal acidification and autophagic flux in studies of cancer, neurodegeneration, and infectious disease (Nature Communications 2024).
• Stock solutions are stable below –20°C for several months; solutions are unstable at room temperature and should be used promptly (APExBIO).

Applications, Limits & Misconceptions

Bafilomycin A1 is widely used for:

• Studying intracellular pH regulation and lysosomal function (AVL-301 – This article expands with practical benchmarks for pH and lysosomal assays).
• Dissecting autophagic flux by blocking autophagosome-lysosome fusion (Nature Communications 2024).
• Investigating osteoclast-mediated bone resorption and its inhibition (LB Broth Miller – This article clarifies applications in bone resorption and troubleshooting compared to general product overviews).
• Modeling disease states such as cancer, neurodegeneration, and infectious disease by perturbing V-ATPase function (Vatalis.info – The current dossier integrates new disease models and workflow parameters beyond prior reviews).

Common Pitfalls or Misconceptions

• Bafilomycin A1 is not a pan-lysosomal inhibitor; it specifically targets V-ATPase-driven acidification.
• It does not inhibit plasma membrane H⁺-ATPases or mitochondrial F₁F₀-ATPases at standard concentrations.
• Long-term storage of solutions at room temperature leads to loss of activity; only stock solutions should be stored below –20°C (APExBIO).
• Bafilomycin A1 does not induce autophagy; it blocks autophagic flux by inhibiting lysosomal acidification.
• Inadequate solubilization in DMSO or aqueous buffers may lead to experimental artifacts.

Workflow Integration & Parameters

Bafilomycin A1 (SKU A8627, APExBIO) is provided as a crystalline solid, soluble in DMSO at concentrations above 10 mM. For experimental use, prepare fresh solutions and use promptly to avoid degradation. Stock solutions (in DMSO) can be stored at –20°C for several months. Avoid repeated freeze-thaw cycles. Recommended working concentrations range from 4 nM (cellular assays) to 400 nM (organismal or tissue studies), with precise titration required for each application (LB Broth Miller – This article provides scenario-driven optimization, whereas this dossier offers atomic parameterization).

When integrating Bafilomycin A1 into workflows, ensure controls for off-target effects and cell viability. For autophagy assays, combine with LC3-II or p62/SQSTM1 detection methods. Shipping is on Blue Ice for small molecule stability. Always consult the lot-specific certificate of analysis from APExBIO for purity and storage instructions.

Conclusion & Outlook

Bafilomycin A1 remains the gold-standard selective V-ATPase inhibitor for probing lysosomal function, intracellular pH, and autophagic flux. Its reproducibility and well-characterized mechanism support a broad array of research in cell biology, disease modeling, and therapeutic screening. Limitations include instability in solution and the need for precise dosing. As research advances, Bafilomycin A1 will continue to serve as a foundational tool for dissecting V-ATPase-dependent processes and validating novel targets (Nature Communications 2024).